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Abstract
Background: There has been a sudden increase in the amount of money donors are willing to
spend on the worldwide HIV/AIDS epidemic. Present plans are to hold most of the money in
reserve and spend it slowly. However, rapid spending may be the best strategy for halting this
disease.
Methods: We develop a mathematical model that predicts eradication or persistence of HIV/AIDS
on a world scale. Dividing the world into regions (continents, countries etc), we develop a linear
differential equation model of infectives which has the same eradication properties as more
complex models.
Results: We show that, even if HIV/AIDS can be eradicated in each region independently, travel/
immigration of infectives could still sustain the epidemic. We use a continent-level example to
demonstrate that eradication is possible if preventive intervention methods (such as condoms or
education) reduced the infection rate to two fifths of what it is currently. We show that, for HIV/
AIDS to be eradicated within five years, the total cost would be ≈ $63 billion, which is within the
existing $60 billion (plus interest) amount raised by the donor community. However, if this action
is spread over a twenty year period, as currently planned, then eradication is no longer possible,
due to population growth, and the costs would exceed $90 billion.
Conclusion: Eradication of AIDS is feasible, using the tools that we have currently to hand, but
action needs to occur immediately. If not, then HIV/AIDS will race beyond our ability to afford it.
Introduction
There has been a sudden increase in the amount of money
donors are willing to spend on the worldwide HIV/AIDS
epidemic. Present plans are to hold most of the money in
reserve and spend it slowly. However, rapid spending may
be the best strategy for halting this disease. The purpose of
this paper is to estimate how and when to best spend the
available money to achieve halting HIV/AIDS as soon as
possible.
In the year 2000, leaders from around the globe derived a
set of goals aimed at making the world safer, healthier and
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more equitable. One of these goals was to halt and begin
to reverse the global HIV/AIDS epidemic by 2015. To real-
ise this goal, in 2006, world leaders pledged to move
towards universal access to HIV prevention, treatment,
care and support by 2010. In the past decade, there has
been a marked decrease in the number of AIDS-related
deaths worldwide and the percentage of individuals living
with HIV has begun to plateau. Indeed, a number of
highly infected countries have seen declines in the
number of new HIV infections [1]. This success is owed
largely to a six-fold increase in financing for HIV activities
in low- and middle-income countries enabling better
access to HIV treatments and care. However, the picture is
not uniformly positive and some countries continue to
see an increase in infections. Also, in spite of the improved
access to HIV treatment and care, the majority of those
who need antiretroviral therapies are not currently receiv-
ing them [1]. As a result, the epidemic is outpacing the
rate at which these drugs are being delivered. In fact, the
number of new infections is significantly greater than the
increase in the number of people on antiretrovirals. Erad-
ication of HIV/AIDS is therefore not achievable using the
current funding model. In the absence of additional fund-
ing, we contend that a significant improvement in results
can be achieved by optimising implementation, i.e. how
donated funds are spent on drug delivery, educational
programs and the distribution of HIV/AIDS prevention
measures.
While estimates on spending have been made for many
scenarios [2-4], these are usually projected in decades or
generations. World events could overtake the HIV/AIDS
epidemic on this time scale, or even be precipitated by it
if it continues to grow [5-9]. Furthermore, donor fatigue
[10] could return, or other crises (tsunamis, wars, etc)
could divert presently committed funds. Is there a quick
fix that could avoid passing the problem on to the next
generation?
Consider, for example, Bill and Melinda Gates, who have
made stopping AIDS the top priority of their foundation
[11], with $60 billion available [12]. As an extreme case,
for instance, ignoring the ability of economies to absorb
so much cash [13], the Gates Foundation might spend all
their money in two years, meeting the worldwide needs of
$27 billion per year for all health needs of all developing
countries [14] (including HIV/AIDS), with the hope that
infrastructure would then be in place and the rest of the
donors would pick up from there. The projected spending
rate of the Gates Foundation is $3 billion per year [15],
which is roughly comparable to the expected annual inter-
est. It is being spread out over 20 years, more than dou-
bling the duration of the epidemic, which has already
lasted over 25 years. Something in between a jump start
and a trickle would seem much more optimal than either
of these extremes.
Furthermore, if we fail to spend at the optimal rate, the
epidemic may blow up. Currently, the percentage of peo-
ple living with HIV has stabilised; however, the overall
number of people living with HIV has steadily increased
[1]. The result is that the epidemic could become totally
out of control or cost immensely more to bring under con-
trol. Many modeling studies have shown a bigger bang for
the buck if the money is spent earlier in an epidemic
[16,17], but none have investigated the optimal course of
spending to bring an epidemic under control as rapidly as
possible and avoid a growing gap [18].
A number of views have been expressed on how to tackle
HIV/AIDS. One approach involves getting back to the fun-
damentals of epidemiology [19] and avoiding AIDS
exceptionalism [20], i.e. treating HIV/AIDS just like other
epidemics. Most people advocate a mixture of prevention
and treatment options [17,21]. One worldwide single
(but not magic) bullet approach that has been proposed
would use the fact that highly active antiretroviral therapy
(HAART) reduces infectivity:
"This optimistic population-based model shows that,
in 45 years, HIV prevalence could be reduced by more
than 70 times from more than 7 cases per 1000 people
to less than 0.1 case per 1000. The number of HIV-
infected people could be reduced from 38 million to
less than 1 million. The cost of therapy would be
about US $7 billion per year, with costs declining from
$15 to $1 billion. Such a programme would be
expected to cost $338 billion over 45 years" [22].
The average cost over the 45 years would be $7.5 billion
per year.
Condoms offer another single-mode approach. Above an
estimable and possibly attainable threshold, condoms
could halt an HIV/AIDS epidemic [23]. If distributed to
1.5 billion men (half the male population of the world),
at 100 condoms per person per year [24], and a cost of
$0.02 each [25], total cost would be $3 billion per year.
(Female condoms have their place, but are about ten
times more expensive each.) For comparison, the USA
spends $12 billion per year domestically on HIV/AIDS,
plus $3 billion per year on HIV/AIDS research [26].
Condoms have the advantage of reducing other STIs (sex-
ually transmitted infections), some of which enhance HIV
infectivity. The threshold for decline of the epidemic is the
product of compliance in use and condom effectiveness,
and there is room for technical improvement of the latter
[24]. The problems to be tackled are not simply behav-BMC Public Health 2009, 9(Suppl 1):S15 http://www.biomedcentral.com/1471-2458/9/S1/S15
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ioural, but also involve design, manufacturing, marketing
and subsidisation [27]. Even in the behavioural realm, the
emphasis on risk factors instead of collective behaviour
may be counterproductive [28,29].
The HIV/AIDS epidemic is often spoken of in terms of
reducing the spread [16], or achieving sustainable financ-
ing [30]. Decades-long investments have been made in
vaccines [31] and more recently in microbicides [32].
These approaches are slow in coming, and do not take
into account the greatly increased amount of cash now
available, at least for the short term. The donor commu-
nity has created the potential of stepping ahead of the
exploding HIV/AIDS epidemic by pooling money faster
than the disease is spreading. Our aim is to use mathemat-
ical modelling to find ways to spend the available money
as fast, efficiently and effectively as possible to bring this
epidemic to a full halt, now, while this transient advan-
tage is still available.
A large number of mathematical models have been used
to describe the epidemiology of HIV [33-46]. These range
from the simple to the complicated, and have used a vari-
ety of techniques to analyse and determine conclusions.
One such technique is that of metapopulation models:
dividing space into distinct regions, within which disease
transmission occurs (often at different rates) and with
"travel" between regions allowing different regions to be
connected. Such models have been used to describe HIV
in a spatial context without resorting to partial differential
equations [47-53].
This paper presents a simple, linear, metapopulation
model that describes the world regions at a number of dif-
ferent scales (continent, country, etc). We use this model
to show that interventions can lead to eradication, but
such interventions must be applied globally, not locally,
and that time is of the essence if our interventions are to
succeed.
An eradication model
In its simplest form, HIV infection can be described by the
classical SI (susceptible-infected) model. The dynamics
are not linear, depending, at a minimum, on the behav-
iour of susceptible (uninfected) individuals, as well as
their interactions with those who are infected. While the
SI model does not capture all the dynamics of HIV, it has
been used to model the disease throughout its entire his-
tory [54-60].
Consider the two-dimensional SI model
Here, Λ is the rate of appearance of new susceptibles, β is
the infection rate, μ is the background death rate and γ is
the death rate due to disease.
This model has two equilibria,
The Jacobian matrix for this system is
with eigenvalues λ = -μ,   -  μ - γ. It follows that the
threshold for eradication [61] in the SI model is
The SI model, while it captures the dynamics of HIV
spread in a population, is difficult to manipulate in a
metapopulation scenario. We propose instead a linear
approximation of this model. The approximation of the
epidemic as linear in the number of infectives is clearly a
coarse one. However, although this model structure does
not capture the transient dynamics of infection and inter-
action, it nevertheless serves as a predictor for eradication.
This is because the major stability analysis carried out on
such models - finding the basic reproductive ratio - con-
sists of linearisation of the nonlinear models. Thus, a lin-
ear version of the model has the advantage of having the
same invasion threshold, although it has the disadvantage
of only describing local stability of the disease-free equi-
librium.
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will always overestimate the epidemic. We shall refer to
this as the I-only model.
This model has only the trivial equilibrium I = 0. If the
trivial equilibrium is stable, then all trajectories will
approach it. If the trivial equilibrium is unstable, then
solutions will increase without bound.
Although the total population without infection is not
constant, it should nevertheless be noted that the I-only
model has the eradication threshold
which is the same eradication threshold as the SI model
(as expected). It follows that there will be eradication in
the I-only model if and only if there is eradication in the
SI model.
To illustrate, we simulated two cases: R0,SI < 1 (Figure 1)
and R0,SI> 1 (Figure 2). Parameters used in the simulations
were Λ = 20 people·years-1, μ =   years-1, γ =   years-
1, with β = 0.00007 people-1years-1 (Figure 1) and β =
0.0002 people-1years-1 (Figure 2). Despite the fact that the
transient dynamics are vastly different in the two models,
the linear approximation has the same eradication thresh-
old as the more accurate SI model and, furthermore,
always overestimates the epidemic. It follows that, for
eradication purposes, the simple, linear model should
determine whether our control methods will be sufficient.
We now extend the SI model to a metapopulation model
with p regions. For 1 ≤ i ≤ p, we can write
Si = susceptible individuals in the ith region;
Ii = infected individuals in the ith region;
Λi = the rate of appearance of new susceptible individ-
uals in the ith region;
μi = background death rate in the ith region;
γi = death rate due to disease in the ith region;
nij = migration rate of susceptible individuals from jth
region to ith region;
dI
dt
I =− −
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When R0 < 1, both models lead to eradication. When R0 < 1, both models lead to eradication. The SI model (solid curve) 
is always below the I-only model (dashed curve). In this case, R0 = 0.8575.
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mij = migration rate of infected individuals from jth
region to ith region.
With these assumptions, we have nii ≡ mii ≡ 0. Then, for i =
1,..., p,
If the system (2) is well-posed, we can find a bound for the
population of susceptibles in each patch. We can then
extend the same idea to obtain the linear system of I-equa-
tions only. (See Appendix for details.)
From Theorem 1 in the Appendix, we have
Thus, the total population of susceptible individuals in
the ith region is limited. So we can write
πi = β × (total population in the ith region without
infection)
di = μi + γi,
where di represents the total death rate in the ith region.
Thus, for i = 1,..., p, the equations of the I-only model are
This can be rewritten as
where I(t) = (I1(t), I2(t),..., Ip(t))T and
Analysis
A two-region example
The simplest nontrivial version of model (2) is the case
when p = 2, which can be presented as follows:
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model (dashed curve) always overestimates the SI model (solid curve). In this case, R0 = 2.45.
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The disease-free equilibrium for model (4) is 
with
By using the next-generation matrix method [62], we can
calculate the basic reproductive ratio for model (4),
where
This is the eradication threshold condition for this simple
case p = 2. The case for p = 2 can be further simplified
under different assumption of the travel (or migration)
between the two regions. Here we list three possibilities.
Case 1
The two regions are isolated from each other. Then, for
each of the two regions, we have, for i = 1, 2,
which has the eradication condition
Case 2
We only allow the susceptible individuals to travel (or
migrate) between the two regions. Then we have
The disease-free equilibrium is again  . How-
ever, the basic reproductive ratio (or the eradication con-
dition for the disease) is given by
Case 3
The travel (or migration) between the two regions is uni-
directional. Without loss of generality, we can assume that
individuals only travel from Region 1 to Region 2. Thus,
we have
The disease-free equilibrium for model (10) is
, with
Using the next-generation matrix method again, we
obtain the basic reproductive ratio
which is also the eradication condition for the disease in
this case.
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nected. All of them depend on the travel rate between the
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two regions to some extent. For example, for Case 2,
denoting
calculation shows that
From this, one can derive conditions for the travel rate of
susceptible individuals which can either help a disease
which is otherwise dying out to persist locally or cause an
otherwise partially persistent disease to persist globally in
the two regions (see Appendix for the details). It follows
that the disease must be reduced within each region and
the effects of travel between regions must be accounted
for. This explains why HIV eradication must be considered
as a world problem, not just a problem for individual
countries, or continents, to tackle independently.
Finding the eradication threshold condition T0
Since system (3) is linear, the stability of the disease-free
equilibrium is determined by the sign of the real parts of
the eigenvalues of the matrix K. The only equilibrium for
the I-only model (3) is the trivial, disease-free equilibrium
(0,...,0). The linear stability of the trivial equilibrium for
(3) is determined by s(K), the stability modulus of K,
which is defined as the maximal real part of all eigenval-
ues of the matrix K. Thus, we can define the overall eradi-
cation threshold as
The trivial equilibrium is globally asymptotically stable if
T0 < 1 (for this linear system (3), the local stability is
equivalent to global stability) and unstable if T0 > 1.
Noting that the right-hand side of I-equations in (2) is
never bigger than the right-hand side of (3) and then by
the standard comparison theorem (see [63,64]), one can
show that T0 is also the condition to guarantee the stabil-
ity of the disease-free equilibrium of system (2). This
implies that HIV can be eradicated under the condition
that T0 < 1, but it can not be eradicated under the condi-
tion that T0 > 1.
A continent-level example
As a more realistic example, we divide the world into six
continents: Africa, Asia, Europe, North America, Oceania
and South America. Infection occurs within each conti-
nent and travel/immigration of infectives occurs between
continents. See Figure 3.
In this case, model (2) is explicitly
Parameters for our model consist of death, birth, immi-
gration and emigration rates at the continental level, as
well as estimates for the number of sexual partners and
infection rates. Immediate data describing these rates does
not exist; however, we can determine many of these
parameters at the continental level using country-specific
data. The birth and death rates have been derived from
crude birth and death rates per 1000 people. The conti-
nental birth and death rates are determined using
weighted averages by country population (see Table 1).
Data was taken from the CIA world factbook 2008 [65].
Net immigration data is also reported in the CIA world
factbook; however, this does not enable us to determine
separate immigration and emigration rates. We can, how-
ever, determine continent-specific immigration and emi-
gration rates from the number of foreign-born individuals
by country. These are individuals who now reside in a par-
ticular country who stated that they were born in a foreign
country on their census form. The Global Migrant Origin
Database [66] gives the number of foreign-born individu-
als by country of origin and country of destination in the
2000 round of country censuses. This data has been sum-
marised to determine the number of foreign born by con-
tinent; that is, individuals who now reside in a continent
who were not born in that continent (see Table 2). Divid-
ing Table 2 by the total number of foreign born gives the
fraction of foreign-born individuals who migrated from
continent A to continent B. If the number of immigrants
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each year is known, these fractions can be used to approx-
imate the number of immigrants and emigrants by conti-
nent.
We use the information in Tables 1 and 2 to determine the
eradication threshold T0. The off-diagonal entries of our
matrix are the off-diagonal entries from Table 2. The diag-
onal entries of our matrix are calculated according to the
formula
where Λi is the influx of new susceptibles, μi is the death
rate (Table 1), β is the infection rate, γ is the AIDS-specific
death rate, ηij is the number of individuals born in conti-
nent j residing on continent i per year (Table 2) and Pi is
the population of continent i (Table 1).
As an example, we choose β = 0.0002 people-1years-1 and
γ  = 0.1 years-1, reflecting the fact that the typical time
course of the disease is ten years. We calculate the influx
of new susceptibles according to the formula
where pi is the continent's birth rate and c is an infected
individual's annual number of (uninfected) sexual part-
ners. We set c = 20; however, the factor   modifies an
individual's annual number of sexual partners according
to the growth (or decline) of the continent they are in.
Thus, for Europe, the annual number of sexual partners is
17, whereas for Oceania the number is 44. These numbers
are likely overestimates, but our intention is to be conserv-
ative in our approach.
If we now intervene and reduce β to 0.0002 x 2/5, then the
overall threshold is  . It follows that
reducing the infection rate to 0.00008 will result in eradi-
cation.
Reducing β by three fifths is, of course, a mammoth task.
Furthermore, this model implicitly assumes that such a
reduction is instantaneous. To compare this to slowly
reducing β over a period of decades, we assumed that β
would be reduced to two fifths of its current value in
twenty years' time, but that reductions would occur evenly
throughout that time. However, we also included a popu-
lation increase of 3% per year. The results are shown in
Figure 4. In this case, the population "overruns" our goal.
The overall T0 is not reduced below one, because the pop-
ulation in twenty years' time will be too high for a 3/5
reduction in the infection rate to lead to eradication.
Costs
We now explore how much these intervention measures
might cost. Interventions include changes in education,
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A continent-level example.
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condoms, drugs and travel restrictions. The costs that can
be applied to these different interventions vary greatly
from region to region. For example, the cost of HAART in
high-income regions is much greater than the cost of the
same drug treatment regime in low-income regions. How-
ever, this lower cost is still expensive compared to the per-
capita national health expenditures. In this section, we
determine the costs that we are going to apply to our
model so that we can determine an optimal way to spend
donor money to eradicate HIV. We list some costs found
in the literature associated with education, HIV testing,
drug therapy and circumcision in Table 3. All costs are
given in US dollars (USD).
Along with the cost of delivering drugs to a patient, it is
also important that we determine what benchmark of
viral load and cell count we will use for initiation of ther-
apy. It is obvious that the costs of delivering therapy and
monitoring will increase if these are started at an earlier
time in HIV infection. For example, it is common practice
to initiate therapy in the developed world when CD4
counts are less than 350 cells/mm3. However, in the devel-
oping world, it is advised that treatment start when CD4
counts are less than 200 cell/mm3. In a study by Vijayara-
ghavan et al. [67], it was found that treating patients with
HIV according to developed- versus developing-world
guidelines is highly cost-effective and may result in sub-
stantial long-term savings. We choose to initiate individu-
als earlier in life for our cost analysis. This means that we
will include a cost of therapy in the upper range of that
listed in Table 3. However, we will only choose this cost
from those for developing countries since the donor funds
are applied mainly to the epidemic in the developing
world.
Note that we assume that the costs of delivering therapy
and health care to HIV infected individuals will stay rela-
tively constant over a short period of time. Since the
donor money will be spent over a span of a few years
rather than decades, this assumption can be expected to
give realistic results. If we were to determine the cost of
such interventons over a long period of time, we must also
include variables describing a decrease in the costs of ther-
apy and testing as drug manufacturing becomes more effi-
cient, the discovery and development of new drugs which
will affect the cost of therapy, the increase in education
and other medical expenses (since administrative costs
and the payment of healthcare workers will increase over
time), etc.
To effectively determine the cost of treatment, we also
must include the possibility of the evolution of drug
resistance [37]. It is difficult to put a dollar figure on the
evolution of drug resistance, since it may occur during dif-
ferent periods of infection in different patients. In our cost
analysis, we choose costs of treatment and testing in the
upper range of that reported (see Table 3), since it is
assumed that the evolution of resistance will increase the
cost of treatment and require more tests to monitor a
patient's viral load and cell count.
Referring back to model (3), it is evident that condoms
and education will reduce πi, while treatment will reduce
πi, but will also decrease di. Education will include con-
dom awareness, but may include other factors, such as
Table 1: Birth rates and death rates by continent [65].
Population Births/Popn Birth Rate Deaths/Popn Death Rate
AF 954879489 33203380 0.0348 12625314 0.0132
AS 4043347897 76536061 0.0189 27947177 0.0069
EU 729546003 7321919 0.0100 8437988 0.0116
NA 527814776 8712554 0.0165 3798366 0.0072
OC 33970173 545421 0.0161 244250 0.0072
SA 383907961 6773241 0.0177 2354551 0.0061
Table 2: Foreign born. Number of foreign born by continent of origin (vertical) and continent of destination (horizontal) [66].
Des/Ori AF AS EU NA OC SA
AF 15973 16987 4263 0 0
AS 286806 298431 13062 1621 32500
EU 5312095 3566013 1167954 252860 1337972
NA 1176374 9690228 8573379 353095 4466748
OC 221003 1380652 2470078 136804 76873
SA 16595 218415 1087422 197314 3324BMC Public Health 2009, 9(Suppl 1):S15 http://www.biomedcentral.com/1471-2458/9/S1/S15
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Reduction in Transmission Figure 4
Reduction in transmission. The effect on the eradication threshold condition T0 of reducing the transmission rate over a 
twenty year period to two fifths of the current value by decreasing the infection rate from 2010 levels to two fifths its current 
value, in 2030. A. Assuming population demographics remain unchanged. B. Assuming 3% population growth per year. Popula-
tion increases over time result in the inability to eradicate the disease using this technique.
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abstinence and monogamy [68]. Travel/immigration
restrictions will reduce mij and mji, but we do not expect
that these will be realistic; past attempts to restrict move-
ment based on travel or immigration have simply driven
the epidemic underground [69].
Note that we assume a population growth of 3% per year.
This corresponds to the maximum population growth rate
reported by the CIA World Factbook. We use the maxi-
mum growth rate so that cost estimates give an upper
bound of what may be realistic for donor spending. We
also assume that HIV-positive cases will continue to
increase at a rate of 3% per year, if no interventions are
undertaken.
Our cost formula is thus
where C is the cumulative cost, n is the proportion of men
who must ultimately receive condoms, m is the fraction of
infected individuals who receive treatment, r is the times-
cale, e is the (fixed) cost of distribution and education,
and θ is the cost of treatment (including the cost of paid
health workers, testing etc). Thus, in the first term of (17),
there are 3 billion men, whose numbers increase by 3%
every year, given 100 condoms each, at a cost of $0.02,
with a fixed condom education campaign of $60 million.
In the second term of (17), we assume that one tenth of
infected individuals require treatment; thus, currently
there are 3.3 million individuals requiring treatment,
whose numbers increase by 3% every year, at an average
cost of $2500 per patient per year.
If we provided condoms to 3/5 of all men over a period of
twenty years and treated nobody, then the cumulative cost
is
Thus, by steadily reducing the infection rate each year, the
costs would blow up, way beyond the available funds and
we would not even reach the eradication threshold. See
Figure 5A.
If we treated everyone who requires treatment for twenty
years, then the cumulative cost is
assuming no fixed costs of condom education.
If instead we aimed to treat 50% of people requiring treat-
ment and provided condoms to 1/5 of all men within
twenty years, then the cumulative cost is
Thus, treatment is significantly more expensive than pre-
vention (as expected).
Conversely, suppose we aimed to reduce infection to two
fifths of its current value and treat everybody infected over
the next five years. Then the cumulative cost is
Thus, we could reach our eradication threshold within
five years, provide treatment to everyone who needs it and
stay within our $60 billion budget (plus interest). See Fig-
ure 5B.
Discussion
We have provided a method for predicting treatment and
prevention levels necessary to eradicate HIV/AIDS, based
on population and immigration data at the continental
Cnmr
r
n
r
(, ,)
.
.
.
.
.
.
=× ×
−
×× × +
+× ×
−
31 0
10 3 1
00 3
100 0 02
33 1 0
10 3 1
00
9
6
ε
3 3
×× θ m.
(17)
C(, , ) $ , , ,. 3 5 0 20 96 793 348 160 =
C(,, ) $ , , , , 0 1 20 221 680 589 500 =
C(, . , ) $ , , , $ , , ,
$,,
1 5 0 5 20 32 244 449 390 110 840 294 800
143 084 744
=+
= , ,. 200
C( , , )$, , , $, , ,
$, , , .
3 5 1 5 19 172 888 920 43 800 370 430
62 973 259 350
=+
=
Table 3: Costs of HIV/AIDS intervention methods.
Intervention Cost (USD) Reference
HIV testing in low-income countries 200-4000 per test [74]
Combination antiretroviral therapy in high-income countries 10000-15000 per patient year [75]
Combination antiretroviral therapy in low-income countries 350-4000 per patient year [75-79]
Costs of monitoring viral load and cell count 25-100 per test [76]
Health education 500-3000 per patient [77,80,81]
Patient out-of-pocket expenses to receive medical care in a low-income area 60-250 [77]
Adult male cirumcision 40-100 [82]
Male condom 0.02 per condom [25]BMC Public Health 2009, 9(Suppl 1):S15 http://www.biomedcentral.com/1471-2458/9/S1/S15
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level. This method is easily applicable to a finer scale, such
as country-level data. The mathematical model is linear,
which allows it to be easily generalised. We have also
developed a formula to estimate the cost of some of these
interventions.
It should be stressed that our model does not attempt to
quantify the prevalence of the disease or the time course
of infection. The model is a predictor of eradication only
and thus should not be used in other contexts. However,
it provides us with insight into the degree of intervention
measures that are needed to eradicate the disease: an
across-the-board reduction in the infection rate by a factor
of three fifths or more, and antiretroviral treatment for
everyone who requires it.
These are steep requirements that will cost a lot of money.
However, we have demonstrated that spending only some
of the money now and saving the rest for the future will
result in a loss of ability to eradicate the disease, using
existing estimates. We have clear, specific goals and they
need to be acted upon immediately.
Our model also demonstrates the folly of focusing locally.
Even if the basic reproductive ratio in all continents were
reduced below one, the disease could still be sustained by
travel or immigration (see Appendix). We note that trav-
ellers/immigrants do not present a high risk factor at
present, but they may be a significant obstacle when the
disease is close to eradication. This is why we must con-
sider HIV/AIDS from a global perspective.
It should be noted that, in addition to our model's obvi-
ous shortcomings, our parameter estimates also have lim-
itations. In particular, the data we use currently assumes
that the disease-specific death rate is negligible, compared
to the background death rate. While this may be approxi-
mately true in some western countries, it is clearly not the
case in Africa [70]. However, while the numbers used here
are illustrative, our calculations of T0 are based on analyt-
ical thresholds. Thus, the sensitivity of the results to our
parameter choices is easily measured: variations in the
data in Tables 1 and 2, as well as formulas (15) and (16)
allows similar calculations to be performed at other scales
than continental (e.g. country-level).
Another assumption that should be noted is that we
assume that travellers/immigrants receive no intervention
help, such as education or treatment. This may be likely if
foreign nationals receive no health care and have limited
access to education, but will not be universally true. How-
ever, in each case we have overestimated the severity of the
disease, in order to provide a strict criterion: if our overall
T0 - calculated from the linear model with the overesti-
mated parameters - is less than one, then we will have
eradication. Our immigration/emigration data did not
include tourism, especially sex tourism [71] which poten-
tially adds a huge effect to the impact of travellers.
Although the cost of a condom is relatively cheap com-
pared to other intervention measures, it is necessary to
acknowledge the fact that a condom taken does not mean
a condom used. Condom promotion requires a well-
developed program infrastructure with excellent logistic
competence of its staff which may be difficult to achieve.
Many areas, especially rural and remote villages, are not
accessible; for example, the healthcare system covers less
than 50% of the population in many sub-Saharan African
countries. In addition, the effectiveness of condoms in
HIV prevention is much less than 100%, perhaps mostly
due to condom failure [24,72]. In addition, there are civil-
war zones, such as eastern Congo, where services cannot
be provided.
This further limits the lack of accessibility to reach out
universally to all parts of the populations. However,
model (3) has the property that decreasing T0 will still be
beneficial. Thus, even if intervention methods are imper-
fect, a large-scale attempt at eradication will still be enor-
mously effective.
Similarly, although we have estimated treatment costs, we
have used aggregate numbers that do not explicitly take
into account many of the specific costs associated with
treatment, such as healthcare worker training. It has been
shown that 100% HAART coverage in sub-Saharan Africa
could be achieved in 10 years, if the number of healthcare
workers were doubled every year [73], but this becomes
expensive quite quickly.
There are, of course, many other intervention methods
that could be examined, such as circumcision, STD con-
trol etc. These methods could be applied together with the
proposed interventions; e.g. condom promotion could be
combined with syphilis treatment without adding lots of
additional costs. As we have learned from family planning
programs, the more methods are offered to a client and
the greater the choice is, the more likely the client is using
one. This is likely to apply for HIV/AIDS control as well;
more methods are advantageous and more likely to lead
to positive results. Recently, UNAIDS has also made this
proposition to promote as many methods as are available
and proven effective.
It is currently advised that countries with different epi-
demic patterns will require different national strategies for
implementing effective HIV prevention programs. Coun-
tries classified as low-level, concentrated, generalised or
hyperendemic should concentrate their efforts on differ-
ent national strategies.BMC Public Health 2009, 9(Suppl 1):S15 http://www.biomedcentral.com/1471-2458/9/S1/S15
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Cumulative cost Figure 5
Cumulative cost. A. The cumulative cost of reducing the infection rate to two fifths of its current rate over the next five 
years and treating everybody who requires it. B. The cumulative cost of reducing the infection rate to two fifths of its current 
rate over the next twenty years (and treating nobody).
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In our model, we have applied the same strategy to all
regions and each region includes countries with one or
more of these classifications. We note, however, that the
education component could be specific to each continent,
or to each country.
Furthermore, although model (3) predicts eradication if
T0 < 1, the threshold also has the property that lower val-
ues are beneficial. Thus, even if actual eradication cannot
be achieved (as may be the case, in reality), intervention
methods such as those mentioned here that reduce T0 will
nevertheless be beneficial.
Thus, for example, if some countries make significant
inroads against the disease, it will still have a global ben-
efit even if eradication does not occur.
We view this model as a starting point.  It provides a crite-
rion for eradication, but we believe that a more accurate
model, one that reflected the time course of the disease in
all regions, is achievable. However, such a model requires
accurate input from all countries; ideally, it could be
updated as more data becomes available, or as new inter-
vention methods are developed. Disease eradication has
occurred on a global scale before, as happened with small-
pox and is currently underway for polio. While the
mechanics of organising the international community in
this way are beyond the scope of this paper, given the scale
of the problem and the immediacy of the required solu-
tion, we believe that this model can provide us with an
easy-to-grasp way of understanding what needs to be
done and when to do it. For the former, our strategy
involves harnessing all existing intervention techniques in
significant strength. For the latter, the time is now.
Appendix
Well-posedness of system (2)
Consider the system (2) with the following initial condi-
tions:
Define
and
The following theorem assures that the system is well-
posed.
Theorem 1
If (S10,, Sp0, I10,, Ip0) ∈ DL, then, for any L >L*, the set DL
is positively invariant for solutions of (2) with (18).
Proof
We first show that the solutions of (2) with (18) are non-
negative. For this purpose, let us rewrite the system (2) as
follows:
where S(t) = (S1(t),, Sp(t))T, I(t) = (I1(t),, Ip(t))T, Λ =
(Λ1,,Λp)T,
and
with ,  for  i = 1,..., p. Noting
that the off-diagonal matrix elements of A(t) are nonneg-
ative, we conclude that the entries of the matrix 
are all nonnegative. Indeed, let
 and rewrite A(t) as
where E denotes the p × p identity matrix. Then all entries
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Noting that the scalar matrix -G(t)E is commutative with
any p × p matrix (hence with  (t)), we have
implying that all entries of   are nonnegative.
Now, from (19), we have
Similarly, for any t ≥ 0, all entries of   are non-
negative. Now, (20) leads to
implying I(t) ≥ 0 for t ≥ 0.
Finally, we show that Si(t) and Ii(t) are bounded for t ≥ 0
and i = 1,..., p. Let N(t) = S1(t) + ... + Sp(t) + I1(t) + ... + Ip(t).
By the nonnegativity of Si(t) and Ii(t), for i = 1,..., p, we
have
This implies that N(t) is bounded with an upper bound
; hence, so are Si(t) and Ii(t)
for t ≥ 0 and i = 1,..., p. This completes the proof. 
Comparison of Case 1 and 2 in Section 3.1
It is obvious from the formulas in (13) that   and 
reflect the influence of travel of susceptible individuals
between the two patches, and hence may be called the
travel-modified basic reproductive ratios for Region 1 and
Region 2, respectively. The following observations are
direct consequences of (12)-(13).
Their verifications are straightforward and are thus omit-
ted.
(A1) Assume   < 1 and   < 1. If n12 > 0 and n21 > 0
satisfy either
or
then   > 1 and   < 1. By symmetry, the conditions
parallel to the above can lead to   < 1 and   > 1.
Here, and in the following, we omit such parallel condi-
tions.
(A2) Assume   < 1 and   > 1. If n12 > 0 and n21 > 0
satisfy either
or
then   > 1 but   > 1.
The biological meanings of (A1)-(A2) can be obtained in
terms of the threshold condition meaning of   and
. For example, (A1) implies that travel of the suscep-
tible individuals can help an otherwise dying out disease
persist locally. Roughly speaking, a larger inflow of sus-
ceptible individuals favours the persistence of the disease
in the region. (A2) shows that appropriate travel rates may
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cause an otherwise partially persistent disease to persist
globally in both regions.
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